Article Text

PDF
PWE-047 Evaluation of PEG-IFN in an ethnically diverse HBV-infected population: 50% of treated patients derive long-term benefit
  1. R Ghani,
  2. A Javaid,
  3. R Marley,
  4. J Lindsay,
  5. P T Kennedy,
  6. G R Foster
  1. Department of Hepatology, The Royal London Hospital, London, UK

Abstract

Introduction Historically pegylated-interferon (PEG-IFN) was reserved for HBeAg+ disease, where seroconversion represented a well defined treatment outcome with reported rates of up to 32%.1 It has recently been shown to benefit a small proportion of patients with HBeAg- disease although patient groups who will benefit remains unclear. The Royal London Hospital treats a large ethnically diverse HBV infected population, thus represents an ideal setting to evaluate the influence of ethnicity on response.

Methods Chronic HBV patients completing treatment with PEG-IFN between 2005 and 2008 were included. A total of 34 patients received PEG-IFN alfa-2a (180 μg once weekly) for 48 weeks. ALT, HBeAg, anti-HBe and viral load (VL) were recorded at 24 and 48 weeks on treatment, 6 and 24 months post treatment. Patients were divided according to e antigen status; HBeAg+ (Group 1, n=25) and HBeAg-(Group 2, n=9). Treatment success was defined by HBeAg seroconversion for Group 1, and a viral load <80 IU/ml and ALT normalisation (<40 IU/l) 6 months after treatment cessation was considered treatment success for HBeAg negative patients (Group 2).

Results For HBeAg+ve patients (Group 1, n=25, 6 East Asian, 4 Bangladeshi, 5 African 6 other): 4 patients (17%) seroconverted, one of whom became anti-HBs+ on treatment. 28% of patients suppressed viral load and normalised ALT while on treatment. 50% of patients progressed to oral antivirals, 25% of whom then seroconverted. Hence 50% of patients either seroconverted or moved to a disease state where therapy was not required. All ethnic groups had a similar response and no pre-treatment factors influenced outcome. For HBeAg-ve disease (Group 2, n=9, 3 Bangladeshi 2 Pakistani 4 other): 3 patients (33%) met the criteria for treatment success at 48 weeks which was upheld over follow-up, one of whom underwent HBsAg seroconversion. Two patients had a sustained reduction in viraemia and inflammation that led to a decision to withhold further therapy. Four patients (44%) required oral antiviral therapy. Hence 56% of patients were managed by interferon alone. Success was most marked in patients from Bangladesh; all three had a full response.

Conclusion This study highlights the benefit of PEG-IFN in HBeAg- disease and its potential advantage in certain ethnic groups. Nevertheless, we saw lower seroconversion rates in HBeAg+ patients than previously reported. Our data suggest that a high ALT is not a requisite for treatment success, while baseline VL, fibrosis stage and age were not determinants of treatment outcome. These data suggest that consideration should be given to PEG-IFN as a treatment option, as opposed to the early initiation of lifelong oral antivirals in treating chronic HBV.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.